PROC - Pharma Company Procaps Beats On Q3 But Lowers FY23 Guidance: Here's Why | Benzinga
Procaps Group SA (NASDAQ: PROC) reported Q3 FY23 revenue of $118.41 million, beating the consensus of $110.4 million and rose 7% Y/Y (+2% Y/Y in constant currency), led by the performance of RX and OTC portfolios.
Gross profit increased 1% Y/Y to $68 million, with a 58% gross margin contracting 343bps Y/Y due to higher costs and an unfavorable product mix.
Adjusted EBITDA fell 4% YY to $22 million in 3Q23, with a margin of 19% (-212 bps Y/Y).
EPS of $0.08 exceeded the consensus of $0.05.
In Q3, the company penned an agreement with BDR Pharmaceuticals for 27 ...